Sartorius Stedim Biotech Shares Bounce 3.85% to €161.90 on the SBF 120
The French bioproduction equipment specialist gains ground in mid-afternoon trading. The stock is among the top gainers on the SBF 120, in a Parisian market trending upwards but marked by long-term rate tensions and a surge in Brent prices.
A 3.85% Bounce Energizes the SBF 120 Without Erasing Annual Decline
Sartorius Stedim Biotech shares gained 3.85% to €161.90 during the session, up from a previous close of €155.90. The stock ranks among the top gainers on the SBF 120, trailing Teleperformance (+6.17%) and Publicis (+4.20%), while the broader index rose by 0.32% and the CAC 40 by 0.39%. Today's movement does not alter the overall picture. Over the year, the stock is still down 19.21%. Over three months, it has declined by 5.13%. In the previous session, the stock had fallen to €159.10 under technical pressure. The current rebound thus mitigates some of the recent drop but does not erase its magnitude. The sector context remains challenging. Brent above $110 and the rise in U.S. yields (the 10-year Treasury reaching 4.63%) weigh on growth stocks. Sartorius, trading at about 32 times this year's expected earnings compared to 22 for the healthcare sector, remains exposed to this backdrop of long-term rates.
Stock Rebounds Above €161 but Remains Distant from Its Moving Averages
From an indicators perspective, today's rebound brings the price close to the 20-day moving average, which stands at €165.54. The negative gap narrows to 2.2%, compared to nearly 4% last Friday. The 200-day average, at €185.39, remains 12.67% above the current price, highlighting the still bearish nature of the underlying trend. The RSI at 41 moves out of the weakness zone without entering bullish territory. The stock is now trading in the middle of the Bollinger Bands (42%), after touching the lower band at the end of April following the quarterly earnings release. As a reminder, on April 23, the company reported a 7.9% increase in revenue to €762 million for the first quarter, with a slight decrease in current EBITDA margin to 30.7% from 30.8% a year earlier, which was cautiously received by the market. The next key date in the financial calendar is the publication of the half-year results for 2026, expected on July 23. Until then, the support zone at €151.50 and the resistance at €188.70 define the technical boundaries observable on the stock.
